* King Pharmaceuticals reports that Altace[R] (ramipril) has overtaken its nearest competitor in the ACE inhibitor market. The company says IMS America weekly prescription data for the week ending May 3 shows Altace has a 21.3% market share among cardiologists. Altace is approved for treatment of hypertension and congestive heart failure after heart attack, and also is approved to reduce the risk of stroke, myocardial infarction and death from cardiovascular causes in patients over age 55 with certain risk factors. Information: James Green, (423) 989-8125.
COPYRIGHT 2002 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group